American Heart Journal
Volume 150, Issue 2 , Pages 243-250 , August 2005

Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease

  • Bryant M. Whiting, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • Cardiology Division, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
    • Corresponding Author InformationReprint requests: Jeffrey L. Anderson, MD, LDS Hospital Cardiovascular Department, 8th Avenue and C Street Salt Lake City, UT 84143.
    • ,
  • Joseph B. Muhlestein, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • Cardiology Division, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
    • ,
  • Benjamin D. Horne, MStat MPH

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • ,
  • Tami L. Bair, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • ,
  • Robert R. Pearson, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • ,
  • John F. Carlquist, PhD

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, Utah
    • Cardiology Division, Department of Internal Medicine, University of Utah, Salt Lake City, Utah
    • ,
  • for the Intermountain Heart Collaborative (IHC) Study Group.

Received 14 November 2003 ,Accepted 17 August 2004.

References 

  1. Kakko S, Kelloniemi J, von Rohr P, et al. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis. 2003;166:285–290
  2. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol level and coronary artery disease in ABCA1 heterozygotes. J Clin Invest. 2000;106:1263–1270
  3. Hsu LA, Ko YL, Hsu KH, et al. Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese. Hum Genet. 2002;110:57–63
  4. Arca M, Montai A, Ombres D, et al. Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet. 2001;60:374–380
  5. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, et al. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen city heart study. J Am Coll Cardiol. 2003;41:1972–1982
  6. Yamakawa-Kobayashi K, Somekawa Y, Fujimura M, et al. Relation of the −514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy. Atherosclerosis. 2002;162:17–21
  7. Juo SH, Han Z, Smith JD, et al. Promoter polymorphisms of hepatic lipase gene influence HDL(2) but not HDL(3) in African American men: CARDIA study. J Lipid Res. 2001;42:258–264
  8. Ma YQ, Thomas GN, Ng MC, et al. The lipoprotein lipase gene HindIII polymorphism is associated with lipid levels in early-onset type 2 diabetic patients. Metabolism. 2003;52:338–343
  9. Larson I, Hoffmann MM, Ordovas JM, et al. The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. Clin Chem. 1999;45:963–968
  10. Ossei-Gerning N, Mansfield MW, Stickland MH, et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol. 1997;17:33–37
  11. Kannel WB. The Framingham Study: its 50-year legacy and future promise. J Atheroscler Thromb. 2000;6:60–66
  12. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens. 1994;7:7S–12S
  13. Ridker PM, Hennekens CH, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2001;344:1959–1965
  14. Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, and inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1998;32:35–41
  15. Taylor GS, Muhlestein JB, Wagner GS, et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J. 1998;136:792–803
  16. Muhlestein JB, Quigley PJ, Ohman EM, et al. Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans. J Am Coll Cardiol. 1992;20:594–598
  17. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 1997;30:1206–1211
  18. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338:86–93
  19. Forester JS. Triglycerides: risk factor or fellow traveler?. Curr Opin Cardiol. 2001;16:261–264
  20. Horne BD, Anderson JL, Muhlestein JB, et al. Genetic burden of polymorphisms related to lipid metabolism increases the risk of angiographic coronary artery disease. Circulation. 2002;106:II–727
  21. Wittrup HH, Tybajærg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation. 1999;99:2901–2907
  22. Eriksson P, Kallin B, van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851–1855
  23. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene is associated with differences in plasma PAI-1 but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837–841
  24. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997;95:59–62
  25. Dugi KA, Brandauer K, Schmidt N, et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation. 2001;104:3057–3062
  26. Zambon A, Deeb SS, Brown BG, et al. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 2001;103:
  27. Whiting BM, Anderson JL, King CA, et al. Does the −514T gene promoter variant of hepatic lipase predict increased HDL levels and reduced risk of angiographic coronary artery disease?. J Am Coll Cardiol. 2003;41:242A;[abstr]
  28. Shohet RV, Vega GL, Anwar A, et al. Hepatic Lipase (LIPC) promoter polymorphism in men with coronary artery disease: allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations. Arterioscler Thromb Vasc Biol. 1999;19:1975–1978
  29. Kuivenhoven JA, deKnijff B, Boer JMA, et al. Heterogeneity at the CETP gene locus-influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1997;17:560–568
  30. Anderson JL, Carlquist JF. Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk. J Am Coll Cardiol. 2003;41:1990–1993
  31. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000;101:1907–1912
  32. Brooks-Wilson A, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336–345
  33. Attie A, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001;42:1717–1726
  34. Marcil M, Yu L, Krimbou L, et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol. 1999;19:159–169
  35. Brousseau ME, Eberhart GP, Dupuis J, et al. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 2000;41:1125–1135
  36. Zwarts KY, Clee SM, Zwinderman AH, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002;61:115–125
  37. Behague I, Poirier O, Nicaud V, et al. Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. Circulation. 1996;93:440–449
  38. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet. 1986;ii:533–537
  39. Gardemann A, Schwartz O, Haberbosch W, et al. Positive association of the fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120–1126
  40. Wilcken DEL, Wang XL, Sim A, et al. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 1996;16:878–882
  41. Kluijtmans LAJ, Kastelein JJP, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573–2577
  42. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023–2031
  43. Brown BG, Cheung MC, Lee AC, et al. Antioxidant vitamins and lipid therapy. End of a long romance?. Arterioscler Thromb Vasc Biol. 2002;22:1535–1546
  44. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002;22:1058–1061

 We gratefully acknowledge the financial support of the Deseret Foundation, Salt Lake City, Utah, and National Heart, Lung, and Blood Institute grant 1 R01 4L071878-01A2.

PII: S0002-8703(04)00595-2

doi: 10.1016/j.ahj.2004.08.034

American Heart Journal
Volume 150, Issue 2 , Pages 243-250 , August 2005

Article Tools

* Image Usage & Resolution